SCHEMBL21392968

SCHEMBL21392968

O=C(CCl)Nc1ccc(Oc2ccc(Cl)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNF4 P78317 1/20 0.76
ALDH1A1 P00352 6/20 0.66
L3MBTL1 Q9Y468 2/20 0.66
FNTA P49354 5/20 0.59
FNTB P49356 5/20 0.59
MITF O75030 3/20 0.56
HTT P42858 3/20 0.56
POLB P06746 1/20 0.56
MAPK1 P28482 1/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
XBP1 P17861 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
NOD2 Q9HC29 1/20 0.54
PNLIP P16233 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11806908 0.93 RNF4 (0.86) RNF4ALDH1A1L3MBTL1MITFHTT
SCHEMBL16922181 0.89 NPC1 (0.66) RNF4ALDH1A1MITFHTTPOLB
SCHEMBL1503954 0.89 NPC1 (0.66) RNF4ALDH1A1MITFHTTPOLB
SCHEMBL3382618 0.86 RNF4 (1.00) RNF4ALDH1A1MITFHTTPOLB
SCHEMBL23748676 0.85 RNF4 (0.73) RNF4ALDH1A1L3MBTL1FNTAFNTB
SCHEMBL4747363 0.85 ALDH1A1 (0.64) RNF4ALDH1A1L3MBTL1FNTAFNTB
SCHEMBL2171671 0.85 L3MBTL1 (0.68) RNF4ALDH1A1L3MBTL1FNTAFNTB
SCHEMBL31703396 0.85 RNF4 (0.73) RNF4ALDH1A1L3MBTL1FNTAFNTB
SCHEMBL22069619 0.84 PNLIP (0.64) HTTMEN1KMT2ANPSR1PNLIP
SCHEMBL31536382 0.84 PNLIP (0.64) HTTMEN1KMT2ANPSR1PNLIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025217513-A1 ACTIVATION OF PLCG2 AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF ALZHEIMER'S DISEASE THE TRUSTEES OF INDIANA UNIVERSITY (US) 2025-10-16 WO disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 RNF4 1274/4885ALDH1A1 4188/4885L3MBTL1 625/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 RNF4 2/4885ALDH1A1 2969/4885L3MBTL1 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.